Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, et al. (October 2023). "The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria". Arthritis & Rheumatology. 75 (10): 1687–1702. doi:10.1002/art.42624. hdl:2027.42/178218. PMID37635643. S2CID263166505.
Bitsadze, V.; Yakubova, F.; Khizroeva, J.; Lazarchuk, A.; Salnikova, P.; Vorobev, A.; Tretyakova, M.; Degtyareva, N.; Grigoreva, K.; Gashimova, N.; Kvaratskheliia, M.; Makatsariya, N.; Kudryavtseva, E.; Tomlenova, A.; Gris, J. C.; Elalamy, I.; Ay, C.; Makatsariya, A. (2024). "Catastrophic Antiphospholipid Syndrome". International Journal of Molecular Sciences. 25 (1): 668. doi:10.3390/ijms25010668. PMC10779422. PMID38203837.
Sciascia S, Radin M, Cecchi I, Levy RA, Erkan D (July 2021). "16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome". Lupus. 30 (8): 1314–1326. doi:10.1177/09612033211020361. PMID34039107. S2CID235215484.
Cheng C, Cheng GY, Denas G, Pengo V (July 2021). "Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review". Blood Reviews. 48: 100788. doi:10.1016/j.blre.2020.100788. PMID33341301. S2CID229343584.
Kruger PC, Eikelboom JW, Douketis JD, Hankey GJ (June 2019). "Deep vein thrombosis: update on diagnosis and management". The Medical Journal of Australia. 210 (11): 516–524. doi:10.5694/mja2.50201. PMID31155730. S2CID173995098.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. (February 2006). "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)". Journal of Thrombosis and Haemostasis. 4 (2): 295–306. doi:10.1111/j.1538-7836.2006.01753.x. hdl:11379/21509. PMID16420554. S2CID9752817.
Islam MA, Alam F, Kamal MA, Wong KK, Sasongko TH, Gan SH (2016). "'Non-Criteria' Neurologic Manifestations of Antiphospholipid Syndrome: A Hidden Kingdom to be Discovered". CNS & Neurological Disorders Drug Targets. 15 (10): 1253–1265. doi:10.2174/1871527315666160920122750. PMID27658514.
Islam MA, Alam F, Gan SH, Cavestro C, Wong KK (March 2018). "Coexistence of antiphospholipid antibodies and cephalalgia". Cephalalgia. 38 (3): 568–580. doi:10.1177/0333102417694881. PMID28952322. S2CID3954437.
Islam MA, Alam F, Wong KK (May 2017). "Comorbid association of antiphospholipid antibodies and migraine: A systematic review and meta-analysis". Autoimmunity Reviews. 16 (5): 512–522. doi:10.1016/j.autrev.2017.03.005. PMID28279839.
Islam MA, Alam F, Sasongko TH, Gan SH (2016). "Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment". Current Pharmaceutical Design. 22 (28): 4451–4469. doi:10.2174/1381612822666160527160029. PMID27229722.
Triplett DA (November 2002). "Antiphospholipid antibodies". Archives of Pathology & Laboratory Medicine. 126 (11): 1424–1429. doi:10.5858/2002-126-1424-AA. PMID12421152.
Rand JH (August 1998). "Antiphospholipid antibody syndrome: new insights on thrombogenic mechanisms". The American Journal of the Medical Sciences. 316 (2): 142–151. doi:10.1097/00000441-199808000-00009. PMID9704667.
Karakasis P, Lefkou E, Pamporis K, Nevras V, Bougioukas KI, Haidich AB, Fragakis N (June 2023). "Risk of Subclinical Atherosclerosis in Patients with Antiphospholipid Syndrome and Subjects With Antiphospholipid Antibody Positivity: A Systematic Review and Meta-analysis". Current Problems in Cardiology. 48 (6): 101672. doi:10.1016/j.cpcardiol.2023.101672. PMID36841314. S2CID257197368.
Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, et al. (October 2023). "The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria". Arthritis & Rheumatology. 75 (10): 1687–1702. doi:10.1002/art.42624. hdl:2027.42/178218. PMID37635643. S2CID263166505.
Bitsadze, V.; Yakubova, F.; Khizroeva, J.; Lazarchuk, A.; Salnikova, P.; Vorobev, A.; Tretyakova, M.; Degtyareva, N.; Grigoreva, K.; Gashimova, N.; Kvaratskheliia, M.; Makatsariya, N.; Kudryavtseva, E.; Tomlenova, A.; Gris, J. C.; Elalamy, I.; Ay, C.; Makatsariya, A. (2024). "Catastrophic Antiphospholipid Syndrome". International Journal of Molecular Sciences. 25 (1): 668. doi:10.3390/ijms25010668. PMC10779422. PMID38203837.
Sciascia S, Radin M, Cecchi I, Levy RA, Erkan D (July 2021). "16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome". Lupus. 30 (8): 1314–1326. doi:10.1177/09612033211020361. PMID34039107. S2CID235215484.
Cheng C, Cheng GY, Denas G, Pengo V (July 2021). "Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review". Blood Reviews. 48: 100788. doi:10.1016/j.blre.2020.100788. PMID33341301. S2CID229343584.
Kruger PC, Eikelboom JW, Douketis JD, Hankey GJ (June 2019). "Deep vein thrombosis: update on diagnosis and management". The Medical Journal of Australia. 210 (11): 516–524. doi:10.5694/mja2.50201. PMID31155730. S2CID173995098.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. (February 2006). "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)". Journal of Thrombosis and Haemostasis. 4 (2): 295–306. doi:10.1111/j.1538-7836.2006.01753.x. hdl:11379/21509. PMID16420554. S2CID9752817.
Islam MA, Alam F, Kamal MA, Wong KK, Sasongko TH, Gan SH (2016). "'Non-Criteria' Neurologic Manifestations of Antiphospholipid Syndrome: A Hidden Kingdom to be Discovered". CNS & Neurological Disorders Drug Targets. 15 (10): 1253–1265. doi:10.2174/1871527315666160920122750. PMID27658514.
Islam MA, Alam F, Gan SH, Cavestro C, Wong KK (March 2018). "Coexistence of antiphospholipid antibodies and cephalalgia". Cephalalgia. 38 (3): 568–580. doi:10.1177/0333102417694881. PMID28952322. S2CID3954437.
Islam MA, Alam F, Wong KK (May 2017). "Comorbid association of antiphospholipid antibodies and migraine: A systematic review and meta-analysis". Autoimmunity Reviews. 16 (5): 512–522. doi:10.1016/j.autrev.2017.03.005. PMID28279839.
Islam MA, Alam F, Sasongko TH, Gan SH (2016). "Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment". Current Pharmaceutical Design. 22 (28): 4451–4469. doi:10.2174/1381612822666160527160029. PMID27229722.
Triplett DA (November 2002). "Antiphospholipid antibodies". Archives of Pathology & Laboratory Medicine. 126 (11): 1424–1429. doi:10.5858/2002-126-1424-AA. PMID12421152.
Rand JH (August 1998). "Antiphospholipid antibody syndrome: new insights on thrombogenic mechanisms". The American Journal of the Medical Sciences. 316 (2): 142–151. doi:10.1097/00000441-199808000-00009. PMID9704667.
Karakasis P, Lefkou E, Pamporis K, Nevras V, Bougioukas KI, Haidich AB, Fragakis N (June 2023). "Risk of Subclinical Atherosclerosis in Patients with Antiphospholipid Syndrome and Subjects With Antiphospholipid Antibody Positivity: A Systematic Review and Meta-analysis". Current Problems in Cardiology. 48 (6): 101672. doi:10.1016/j.cpcardiol.2023.101672. PMID36841314. S2CID257197368.
Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, et al. (October 2023). "The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria". Arthritis & Rheumatology. 75 (10): 1687–1702. doi:10.1002/art.42624. hdl:2027.42/178218. PMID37635643. S2CID263166505.
Sciascia S, Radin M, Cecchi I, Levy RA, Erkan D (July 2021). "16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome". Lupus. 30 (8): 1314–1326. doi:10.1177/09612033211020361. PMID34039107. S2CID235215484.
Cheng C, Cheng GY, Denas G, Pengo V (July 2021). "Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review". Blood Reviews. 48: 100788. doi:10.1016/j.blre.2020.100788. PMID33341301. S2CID229343584.
Kruger PC, Eikelboom JW, Douketis JD, Hankey GJ (June 2019). "Deep vein thrombosis: update on diagnosis and management". The Medical Journal of Australia. 210 (11): 516–524. doi:10.5694/mja2.50201. PMID31155730. S2CID173995098.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. (February 2006). "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)". Journal of Thrombosis and Haemostasis. 4 (2): 295–306. doi:10.1111/j.1538-7836.2006.01753.x. hdl:11379/21509. PMID16420554. S2CID9752817.
Islam MA, Alam F, Gan SH, Cavestro C, Wong KK (March 2018). "Coexistence of antiphospholipid antibodies and cephalalgia". Cephalalgia. 38 (3): 568–580. doi:10.1177/0333102417694881. PMID28952322. S2CID3954437.
Karakasis P, Lefkou E, Pamporis K, Nevras V, Bougioukas KI, Haidich AB, Fragakis N (June 2023). "Risk of Subclinical Atherosclerosis in Patients with Antiphospholipid Syndrome and Subjects With Antiphospholipid Antibody Positivity: A Systematic Review and Meta-analysis". Current Problems in Cardiology. 48 (6): 101672. doi:10.1016/j.cpcardiol.2023.101672. PMID36841314. S2CID257197368.